Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms-Reference-Cited by-同舟云学术

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms

Published:2015-04-03 Issue:11 Volume:29 Page:2134-2142
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Molenaar R J,Thota S,Nagata Y,Patel B,Clemente M,Przychodzen B,Hirsh C,Viny A D,Hosano N,Bleeker F E,Meggendorfer M,Alpermann T,Shiraishi Y,Chiba K,Tanaka H,van Noorden C J F,Radivoyevitch T,Carraway H E,Makishima H,Miyano S,Sekeres M A,Ogawa S,Haferlach T,Maciejewski J P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201591.pdf

Reference34 articles.

1. Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE . The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta Rev Cancer 2014; 1846: 326–341.

2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.

3. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.

4. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739–744.

5. Ponnaluri VK, Maciejewski JP, Mukherji M . A mechanistic overview of TET-mediated 5-methylcytosine oxidation. Biochem Biophys Res Commun 2013; 436: 115–120.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia;Human Pathology;2024-07

2. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease;British Journal of Haematology;2024-05-09

3. RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells;Science Advances;2024-04-19

4. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia;Leukemia;2024-04-10

5. Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches;Frontiers in Oncology;2024-02-12